Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome

NCT04776876 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The study will not be opening. Support was withdrawn.

Conditions

Advanced Neuroendocrine Neoplasm
Carcinoid Syndrome

Interventions

BIOLOGICAL: Retifanlimab
DRUG: Telotristat Ethyl

Sponsor

M.D. Anderson Cancer Center